Fairfield Market Research Acute Lung Injury Treatment Market Size and Share Report, 2029

Acute Lung Injury Treatment Market

Global Industry Analysis (2018 - 2021) - Growth Trends and Market Forecast (2022 - 2029)

Published Date: Upcoming | Format:

Industry: Pharmaceuticals & Biotechnology

Request TOC Request Customization $4,995.00Prebook

Steady Demand for Effective Treatment for Acute Lung Injury Prevails

One of the leading causes of morbidity, and mortality in critically ill patients, acute lung injury has a high incidence rate worldwide. As the mortality rate associated with the condition has been on a higher side, an effective treatment also continues to be in demand. Global acute lung injury market though remains on a steady uptrend is likely to be experiencing a dynamic landscape majorly on the research forefront. Significant players competing in acute lung injury treatment market are expected to invest their core research strength in novel therapies, and treatments that effectively enhance the outcome and thereby improve the quality of life of patients to a measurable extent. The therapeutic complications and associated high costs will however limit long-term market growth. Inadequate adoption of diagnosis aids like portable spirometers, and digital radiography machines is also expected to challenge rapid growth of acute lung injury treatment market.

Global Burden of Lung-related Diseases Continues to Pile up

The worldwide expanding elderly patient population, and notably growing awareness about health diagnostics are expected to give acute lung injury treatment market a collective push. Advent of technology that has been aiding in the exploration of new potential treatment methods for acute lung injury treatment will also bode well for market. Above all these factors, rising prevalence of lung-related disease conditions will predominantly drive the growth of acute lung injury treatment market. The Global Burden of Disease Study affirms the remarkably surging prevalence of lung-related conditions. Asthma stands among the most common chronic diseases in children, and adolescents, reportedly affecting over 14% of children globally. Chronic obstructive pulmonary disease (COPD) had more than 250 million recorded cases worldwide in 2016 and accounts for around 3 million deaths each year. Pneumonia also remains one of the leading causes of death of millions every year, including children under five years old. Besides, there are some other factors as well that may be responsible for acute lung injury, which include accidents, hypoxia, sepsis, excessive smoking, accidental inhalation of noxious fumes, and major trauma.

Preference for Mechanical Ventilation Intact, Clinical Trials of More Effective Treatment Alternatives in Pipeline

Mechanical ventilation remains the most preferred supportive method of acute lung injury treatment as it allows sufficient and frequent air/oxygen supply at tidal volumes, and boosts progress in oxygenation. Tracheotomy process is often recommended for those patients who require lengthy mechanical ventilation. Extracorporeal membrane oxygenation (ECMO) will continue to be sought-after for a limited number of cases. As far as the introduction of newer treatment alternatives is concerned, several clinical trials have been in progress, among which the FP-1201-lyo treatment for acute lung injury is currently in phase III of its clinical trials and expects the European marketing authorisation soon. Faron Pharmaceuticals, Ltd. is also involved in the development of multiple pharmacological treatments for acute lung injury, wherein the role of a consortium that comprises the European Commission, and Traumakine programme (University of Torino, University of Turku, and University College London Hospital) will be crucial. A couple of years ago, Windtree Therapeutics had published the results of its lung deposition study of aerosolised Lucinactant. As acute lung injury patients frequently suffer from augmented vascular leakage, reduced leakage is likely to remain the key objective of all therapies, and treatments.

Acute Lung Injury Remains an Unmet Medical Need

Although there had been a lot of developments in terms of the overall disease understanding, epidemiology, and pathophysiology, the fact repeatedly highlights a degraded quality of life of patients that lasts the lifetime. The rate of morbidity, and mortality also needs to be reduced to a large extent. On one side, acute lung injury treatment market exhibits a stable growth curve based on sustained demand but on the other hand, greater disease prevalence and ineffectiveness of the available treatments continue to hamper it as an unmet medical condition. Global acute lung injury treatment market thus anticipates some truly novel therapeutic procedures that would come with improved clinical outcomes. R&D in acute lung injury treatment market space is growing dynamically over the recent past and more focus on research will benefit the progress of acute lung injury treatment market in long run. Research has identified some of the biological markers associated with unsuccessful clinical outcomes. Researchers have also reported novel outcomes in the areas of lung-protective ventilation strategies, and fluid conservation, in form of improved patient survival rates. Moreover, a lot of interest has been developing around the potentially effective therapies like nutritional strategies, and statin therapy.

Pricing Remains a Deterrent Facing Developing, and Emerging Markets

Regional analysis of global acute lung injury market reveals that the US will continue to be dominant on account of the highest prevalence of the disease. Europe is also an important market given the disease prevalence, and the offerings of sophisticated European healthcare industry. On the flipside, the expensive price point associated with acute lung injury treatment continues to make it an unaffordable medical need across a majority of developing, and emerging nations.

Key Companies in Global Acute Lung Injury Treatment Market

Bayer AG, Glaxosmithkline Plc, Teva Pharmaceutical Industries Ltd., APEPTICO Forschung und Entwicklung GmbH, Medtronic Plc., Bachem Holding AG, Pfizer Inc., General Electric Company, Ony Biotech Inc, Koninklijke Philips N.V., Linde Plc., Altor BioScience Corporation, Carolus Therapeutics, Inc., Discovery Laboratories, Inc., and Faron Pharmaceuticals Ltd. are some of the major vendors driving competition in global acute lung injury treatment market landscape. The vendor landscape is remarkably competitive and is likely to be driven by the growing focus on R&D.

The Acute Lung Injury Treatment Market Has Been Segmented As Below:

By Injury Type

  • Direct
  • Indirect

By Therapy

  • Medication
  • Pharmacotherapy
  • Fluid Management
  • Inhaled nitric oxide

By Device

  • Mechanical Ventilator
  • Adjunctive Procedure Device

By End User

  • Hospitals and Clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Russia
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
  • Latin America
    • Brazil
    • Mexico
  • MEA
    • Saudi Arabia
    • UAE
    • South Africa

Key Elements Included In The Study: Global Acute Lung Injury Treatment Market

  • Acute Lung Injury Treatment Market by Product/Technology/Grade, Application/End-user, and Region
  • Executive Summary (Opportunity Analysis and Key Trends)
  • Historical Market Size and Estimates, Value, 2018 - 2021
  • Market Value at Regional and Country Level, 2022 - 2029
  • Market Dynamics and Economic Overview
  • Market Size in Value, Growth Rates, and Forecast Figures, 2022 - 2029
  • Competitive Intelligence with Financials, Key Developments, and Portfolio of Leading Companies 
  • Regional and Product/Grade/Application/End-user Price Trends Analysis
  • Value Chain and Five Force’s Analysis
  • Regional/Sub-region/Country Market Size and Trend Analysis
  • Company Market Share Analysis and Key Player Profiles

Post Sale Support, Research Updates & Offerings

We value the trust shown by our customers in Fairfield Market Research. We support our clients through our post sale support, research updates and offerings.

  • The report will be prepared in a PPT format and will be delivered in a PDF format.
  • Additionally, Market Estimation and Forecast numbers will be shared in Excel Workbook.
  • If a report being sold was published over a year ago, we will offer a complimentary copy of the updated research report along with Market Estimation and Forecast numbers within 2-3 weeks’ time of the sale.
  • If we update this research study within the next 2 quarters, post purchase of the report, we will offer a Complimentary copy of the updated Market Estimation and Forecast numbers in Excel Workbook.
  • If there is a geopolitical conflict, pandemic, recession, and the like which can impact global economic scenario and business activity, which might entirely alter the market dynamics or future projections in the industry, we will create a Research Update upon your request at a nominal charge.


  • The segmentation/company profiles/countries depicted above may vary in the actual report.

Request Table of Contents

Our Research Methodology

Considering the volatility of business today, traditional approaches to strategizing a game plan can be unfruitful if not detrimental. True ambiguity is no way to determine a forecast. A myriad of predetermined factors must be accounted for such as the degree of risk involved, the magnitude of circumstances, as well as conditions or consequences that are not known or unpredictable. To circumvent binary views that cast uncertainty, the application of market research intelligence to strategically posture, move, and enable actionable outcomes is necessary.

View Methodology
Fairfield Quality assured
Fairfield Confidentiality assured
Fairfield Custom research services